CX Institutional
- SEC CIK
- 0001737089
- Latest filing
- Jul 1, 2026
REGN holding history
Regeneron Pharmaceuticals, Inc. in every 13F filed by CX Institutional, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
REGN overviewAll 13F holders of REGNFull Q2 2026 holdings
- Shares (Q2 2026)
- 385
- Value
- $240.0K
- % of portfolio
- <0.1%
- Quarters held
- 19
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 385 | $240.0K | <0.1% | −1−0.3% | Reduced | Holders |
| Q1 2026 | 386 | $298.0K | <0.1% | +12+3.2% | Added | Holders |
| Q4 2025 | 374 | $289.0K | <0.1% | −7−1.8% | Reduced | Holders |
| Q3 2025 | 381 | $214.0K | <0.1% | +79+26.2% | Added | Holders |
| Q2 2025 | 302 | $159.0K | <0.1% | +22+7.9% | Added | Holders |
| Q1 2025 | 280 | $178.0K | <0.1% | −18−6.0% | Reduced | Holders |
| Q4 2024 | 298 | $212.3K | <0.1% | −11−3.6% | Reduced | Holders |
| Q3 2024 | 309 | $324.8K | <0.1% | +7+2.3% | Added | Holders |
| Q2 2024 | 302 | $317.4K | <0.1% | +2+0.7% | Added | Holders |
| Q1 2024 | 300 | $288.7K | <0.1% | −15−4.8% | Reduced | Holders |
| Q4 2023 | 315 | $276.7K | <0.1% | +4+1.3% | Added | Holders |
| Q3 2023 | 311 | $255.9K | <0.1% | +30+10.7% | Added | Holders |
| Q2 2023 | 281 | $201.9K | <0.1% | −18−6.0% | Reduced | Holders |
| Q1 2023 | 299 | $246.5K | <0.1% | +12+4.2% | Added | Holders |
| Q4 2022 | 287 | $207.1K | <0.1% | +287 | New | Holders |
| Q3 2022 | 0 | $0 | 0.0% | −154−100.0% | Sold out | Holders |
| Q2 2022 | 154 | $91.0K | <0.1% | +154 | New | Holders |
| Q4 2021 | 0 | $0 | 0.0% | −133−100.0% | Sold out | Holders |
| Q3 2021 | 133 | $80.0K | <0.1% | −5−3.6% | Reduced | Holders |
| Q2 2021 | 138 | $77.0K | <0.1% | +53+62.4% | Added | Holders |
| Q1 2021 | 85 | $40.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.